KarXT FDA Approval Status
Last updated by Judith Stewart, BPharm on Oct 10, 2023.
FDA Approved: No
Brand name: KarXT
Generic name: xanomeline and trospium
Company: Karuna Therapeutics, Inc.
Treatment for: Schizophrenia; Alzheimer’s Disease Psychosis
KarXT (xanomeline and trospium) is an M1/M4 muscarinic receptor agonist and antimuscarinic combination in development as an antipsychotic treatment for schizophrenia and psychosis related to Alzheimer’s disease.
- Xanomeline is a cholinergic agonist that acts primarily at the M1 and M4 muscarinic receptors to treat symptoms associated with schizophrenia and psychosis related to Alzheimer’s disease. Stimulation of the muscarinic receptors by xanomeline can cause severe and undesirable cholinergic adverse effects, which are thought to be reduced by the addition of the antimuscarinic agent trospium.
Development timeline for KarXT
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.
